RET和MEK联合抑制治疗RET融合阳性且伴有获得性BRAF融合的NSCLC：病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-08-28 DOI:10.1016/j.jtocrr.2024.100724

Jacobi B. Hines MD , Benjamin C. Bowar PharmD , Margaret Colleton MMS , Lydia Chelala MD , Peng Wang MD , Angad A. Chadha MD , Jeremy Segal MD , Christine M. Bestvina MD

{"title":"RET和MEK联合抑制治疗RET融合阳性且伴有获得性BRAF融合的NSCLC：病例报告","authors":"Jacobi B. Hines MD , Benjamin C. Bowar PharmD , Margaret Colleton MMS , Lydia Chelala MD , Peng Wang MD , Angad A. Chadha MD , Jeremy Segal MD , Christine M. Bestvina MD","doi":"10.1016/j.jtocrr.2024.100724","DOIUrl":null,"url":null,"abstract":"<div><div><em>RET</em> fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a <em>CCDC6::RET</em> fusion treated with selpercatinib. Testing at the time of progression revealed a new <em>SKAP2</em><em>:</em>:BRAF fusion. She was then treated with a combination of selpercatinib and trametinib, which led to a likely partial response, despite the combination demonstrating side effects. This case report details the first known instance of NSCLC with a <em>RET</em> fusion developing resistance by means of a <em>BRAF</em> fusion, treated with combined RET and MEK inhibition.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 11","pages":"Article 100724"},"PeriodicalIF":3.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report\",\"authors\":\"Jacobi B. Hines MD , Benjamin C. Bowar PharmD , Margaret Colleton MMS , Lydia Chelala MD , Peng Wang MD , Angad A. Chadha MD , Jeremy Segal MD , Christine M. Bestvina MD\",\"doi\":\"10.1016/j.jtocrr.2024.100724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><em>RET</em> fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a <em>CCDC6::RET</em> fusion treated with selpercatinib. Testing at the time of progression revealed a new <em>SKAP2</em><em>:</em>:BRAF fusion. She was then treated with a combination of selpercatinib and trametinib, which led to a likely partial response, despite the combination demonstrating side effects. This case report details the first known instance of NSCLC with a <em>RET</em> fusion developing resistance by means of a <em>BRAF</em> fusion, treated with combined RET and MEK inhibition.</div></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 11\",\"pages\":\"Article 100724\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000948\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000948","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

1%至2%的NSCLC存在RET融合。尽管像色瑞帕替尼这样的RET抑制剂很有效，但不可避免地会产生耐药性。我们报告了一例28岁女性患者的病例，该患者患有复发性NSCLC，并伴有CCDC6::RET融合，曾接受过舍培卡尼治疗。病情恶化时的检测发现了新的 SKAP2::BRAF 融合。随后，她接受了塞培卡替尼和曲美替尼的联合治疗，尽管联合治疗出现了副作用，但她很可能获得了部分应答。本病例报告详细介绍了第一例已知的RET融合的NSCLC患者通过BRAF融合产生耐药性，并接受RET和MEK联合抑制治疗的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report

RET fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a CCDC6::RET fusion treated with selpercatinib. Testing at the time of progression revealed a new SKAP2::BRAF fusion. She was then treated with a combination of selpercatinib and trametinib, which led to a likely partial response, despite the combination demonstrating side effects. This case report details the first known instance of NSCLC with a RET fusion developing resistance by means of a BRAF fusion, treated with combined RET and MEK inhibition.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊